The U.K. RNA interference company Silence Therapeutics PLC is raising £5.7 million ($8.8 million) in funding from new and existing investors to extend its cash runway to nearly the end of 2014. The new funding will allow its lead anticancer RNAi compound Atu027 to reach proof of concept.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?